Another significant change occurred in the 340B program after a federal judge ruled in favor of Genesis Healthcare in the Genesis Healthcare, Inc. v. Becerra court ruling on November 3, 2023.
The federal judge cited that the Health Resources and Services Administration’s (“HRSA”) definition of a “patient” was too broad and that covered entities do not need to initiate a prescription for it to be filled under 340B pricing. This has large implications on the patient definition a covered entity may use to qualify patients eligible for 340B drug pricing.
The 340B program has seen considerable change over the last few years. Covered entities have had to navigate temporary COVID-19 regulations, manufacturer restrictions, and, now, prospective changes to their patient definition. Covered entities should reassess how these changes impact their overall 340B program strategy, from mixed-use drug utilization to leveraging retail and contract pharmacies.
The 340B Drug Pricing Program plays a crucial role in the United States national healthcare system, aiming to enhance access to affordable medications, particularly for patient populations insured by Medicare and Medicaid. Entities like hospitals and clinics benefit from reduced drug prices and pass those savings on to the patients in their care, ultimately enhancing their ability to provide quality healthcare. Recent developments, such as the Genesis Healthcare, Inc. v. Becerra court ruling, have brought the program into focus.
The overarching concern in any 340B discussion is patient access and affordability. Any legislative changes to the 340B program may influence the program’s ability to fulfill its mission of supporting vulnerable populations, potentially altering the landscape of medication affordability. A court ruling also holds implications for healthcare providers participating in the 340B program. Changes in drug pricing and program regulations could significantly impact the financial landscape of participating entities.
Case Study: Medical Center Achieves Sustainable Growth With Its 340B Program
Before the Genesis Healthcare ruling, the 340B program faced controversies, including debates over eligibility criteria and concerns about potential misuse. In the recent case, Genesis Healthcare, Inc. challenged the Health Resources and Services Administration (“HRSA”) after being removed as a qualifying participant in the 340B program. HRSA claimed that Genesis Healthcare was dispensing drugs to individuals who were ineligible because they were not “patients” of Genesis Healthcare. The court ruling addressed concerns from both sides, prompting a closer examination of the program’s structure and function. Ultimately, a federal judge ruled in favor of Genesis Healthcare, citing that HRSA’s definition of a “patient” was too broad and that covered entities do not need to initiate a prescription for it to be filled under 340B pricing. Rather, covered entities can dispense 340B drugs so long as the covered entity has an ongoing relationship with the patient in question. The expanded definition of an eligible patient potentially provides greater opportunity for covered entities to take advantage of 340B benefits.
Looking ahead, the Genesis Healthcare ruling prompts speculation about the long-term effects on the 340B program. Now more than ever, it’s imperative that healthcare providers evaluate the benefits of 340B participation and eligibility. The result of the court ruling opens providers to broader access to 340B discounts, which would likely increase cost savings on pharmaceuticals. This can directly contribute to financial health by reducing the expenses associated with procuring medications for eligible patients. Additionally, the 340B program is designed to benefit underserved populations. Expanding access to discounted drugs can improve healthcare providers’ ability to reach and serve these communities, addressing health disparities and meeting the needs of a broader patient demographic.
In conclusion, the 340B drug pricing program, shaped by the recent Genesis Healthcare, Inc. v. Becerra ruling, stands at a crossroads. As we navigate the evolving landscape, it is imperative to consider the program’s impact on healthcare providers, patients, and the broader healthcare system. The ongoing dialogue surrounding the 340B program remains crucial to ensuring its effectiveness in meeting the healthcare needs of underserved communities.
Author: Dakota Nelson | [email protected]
Contact Us
Reach out to Withum’s Healthcare Advisory Services Team to request a free demo of our 340B Management Tool.
